National Cancer Center Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2019

  1. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 5, pp. 686-700

2018

  1. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 2, pp. 194-206

2017

  1. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

    New England Journal of Medicine, Vol. 377, Núm. 4, pp. 352-360